Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Bought by Blue Trust Inc.

Blue Trust Inc. lifted its position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) by 203.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,827 shares of the company’s stock after purchasing an additional 26,698 shares during the period. Blue Trust Inc.’s holdings in Sana Biotechnology were worth $65,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in SANA. China Universal Asset Management Co. Ltd. lifted its stake in shares of Sana Biotechnology by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,341 shares of the company’s stock worth $77,000 after acquiring an additional 4,554 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Sana Biotechnology in the 4th quarter valued at approximately $239,000. Clarius Group LLC boosted its stake in shares of Sana Biotechnology by 78.1% during the 4th quarter. Clarius Group LLC now owns 112,500 shares of the company’s stock valued at $183,000 after buying an additional 49,316 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in shares of Sana Biotechnology during the third quarter worth approximately $29,000. Finally, Barclays PLC increased its stake in shares of Sana Biotechnology by 126.6% in the third quarter. Barclays PLC now owns 318,910 shares of the company’s stock worth $1,325,000 after buying an additional 178,179 shares during the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Sana Biotechnology

In related news, insider Fmr Llc sold 290,912 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the transaction, the insider now owns 4,541,511 shares in the company, valued at $29,474,406.39. The trade was a 6.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 31.10% of the company’s stock.

Sana Biotechnology Price Performance

SANA stock opened at $2.88 on Tuesday. The firm has a fifty day moving average price of $2.76 and a two-hundred day moving average price of $3.51. Sana Biotechnology, Inc. has a 1-year low of $1.52 and a 1-year high of $12.00. The firm has a market cap of $643.02 million, a price-to-earnings ratio of -2.06 and a beta of 1.60.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. TD Cowen upgraded shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. HC Wainwright increased their price target on shares of Sana Biotechnology from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, JMP Securities downgraded Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Sana Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.25.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.